Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPN 01087

Drug Profile

IPN 01087

Alternative Names: 3BP-227; 177Lu-3BP-227; 177Lu-IPN01087; IPN 1087; IPN-01087 - Ipsen; IPN-01087A - Ipsen; IPN01087; Lutetium-(177lu)-3BP-227; Lutetium-(177lu)-IPN01087

Latest Information Update: 28 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3B Pharmaceuticals
  • Developer 3B Pharmaceuticals; Ipsen Biopharmaceuticals
  • Class Antineoplastics; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Neurotensin type 1 receptor modulators; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Pancreatic cancer
  • No development reported Small cell lung cancer

Most Recent Events

  • 28 May 2019 Phase-I clinical trials in Pancreatic cancer in Germany (IV), before May 2019 (3B Pharmaceuticals, pipeline May 2019)
  • 22 May 2018 Ipsen plans a phase I/II trial for Solid Tumours in France , (NCT03525392)
  • 15 May 2018 Preclinical trials in Solid tumours in France (IV) (Ipsen pipeline, May 2018 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top